Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

SML3829

Sigma-Aldrich

CADD522

≥98% (HPLC)

Synonym(s):

2-[(3,4-Dichlorophenyl)carbamoyl]bicyclo[2.2.1]hept-5-ene-3-carboxylic acid, 3-[(3,4-Dichlorophenyl)carbamoyl]bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, 3-[[(3,4-Dichlorophenyl)amino]carbonyl]bicyclo[2.2.1]hept-5-ene-2-carboxylic acid

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C15H13Cl2NO3
CAS Number:
199735-88-1
Molecular Weight:
326.17
UNSPSC Code:
12352200
NACRES:
NA.21

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

SMILES string

O=C(C1C2C=CC(C1C(NC3=CC=C(C(Cl)=C3)Cl)=O)C2)O

Biochem/physiol Actions

CADD522 is a cell-permeable, bioavailable, non-toxic carbamoyl-bicycloheptene-carboxylate that inhibits RUNX2-DNA binding, thereby increases RUNX2 stability, upregulates RUNX2 expression levels and downregulates RUNX2 responsive genes transcription. CADD522 inhibits mitochondrial oxidative phosphorylation by decreasing the mitochondrial oxygen consumption rate and ATP production in human breast cancer cells in a RUNX2-independent manner. CADD-522 suppresses in vivo tumor growth and metastasis, and appreciably prolongs the survival rates without the need for surgery or chemotherapy.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis
Oncotarget, 11(43), 3863-3885 (2020)
YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522
Journal of bone oncology, 39, 100474-100474 (2023)
Myoung Sook Kim et al.
Oncotarget, 8(41), 70916-70940 (2017-10-21)
The RUNX2 transcription factor promotes breast cancer growth and metastasis through interactions with a variety of cofactors that activate or repress target genes. Using a direct drug discovery approach we identified CADD522 as a small molecule that inhibits the DNA

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service